Cell wall inhibitors - Pipeline Insight, 2024

This “Cell wall inhibitors - Pipeline Insight, 2024” report provides comprehensive insights about 30+ companies and 30+ pipeline drugs in Cell wall inhibitors pipeline landscape. It covers the pipeline drug profiles, including clinical and nonclinical stage products. It also covers the therapeutics assessment by product type, stage, route of administration, and molecule type. It further highlights the inactive pipeline products in this space.

Geography Covered

• Global coverage

Cell wall inhibitors Understanding

Cell wall inhibitors: Overview

Cell wall biosynthesis inhibitors (CBIs) have historically been one of the most effective classes of antibiotics. They are the most extensively used class of antibiotics and their importance is exemplified by the ß-lactams and glycopeptide antibiotics. They control Gram-negative and Gram-positive bacterial infection by inhibition of cell wall synthesis and have been used for many decades.

ß-Lactam antibiotics: They are a broad class of antibiotics that inhibit cell wall synthesis, consisting of all antibiotic agents that contain a ß-lactam nucleus in their molecular structures. Some commonly used ß-Lactam antibiotics include penicillins, ciclosporins, monobactams, and carbapenems. They are bactericidal and act by inhibiting the synthesis of peptidoglycan layers in the bacterial cell wall.- Glycopeptide antibiotics: They are composed of glycosylated cyclic or polycyclic nonribosomal peptides. Some important glycopeptide antibiotics include vancomycin, teicoplanin, telavancin, bleomycin, and ramoplanin. They inhibit the synthesis of cell walls in susceptible microbes by inhibiting peptidoglycan synthesis.

Although ß-lactam antibiotics and glycopeptide antibiotics can treat bacterial infections by inhibiting cell wall biosynthesis, incorrect or excessive use of antibiotics in recent years has increased antibiotic resistance, resulting in less effective treatments than before. The use of bacterial cell wall biosynthesis inhibitors continues to be an effective way to combat bacterial infections.

Report Highlights

The companies and academics are working to assess challenges and seek opportunities that could influence Cell wall inhibitors R&D. The therapies under development are focused on novel approaches for Cell wall inhibitors.

Cell wall inhibitors Emerging Drugs Chapters

This segment of the Cell wall inhibitors report encloses its detailed analysis of various drugs in different stages of clinical development, including phase III, II, I, preclinical and Discovery. It also helps to understand clinical trial details, expressive pharmacological action, agreements and collaborations, and the latest news and press releases.

Cell wall inhibitors Emerging Drugs

CONTEPO: Nabriva Therapeutics CONTEPO (previously referred to as ZTI-01 and ZOLYD) is an investigational, first-in-class epoxide antibiotic with a broad spectrum of bactericidal Gram-negative and Gram-positive activity, including activity against most contemporary MDR strains that threaten hospitalized patients.

The FDA has granted CONTEPO Qualified Infectious Disease Product (QIDP) and Fast Track designations for: Complicated urinary tract infections (c UTI), complicated intra-abdominal infections (c IAI), hospital-acquired bacterial pneumonia (HABP) / Ventilator-associated bacterial pneumonia (VABP), acute bacterial skin and skin structure infections (ABSSSI). It is currently in preregistration phase of development and is being developed byNabrivaTherapeutics.

Tebipenem pivoxil: Spero Therapeutics Tebipenem HBr, an oral carbapenem that completed a pivotal Phase 3 clinical trial, ADAPT-PO, for the treatment of complicated urinary tract infections and acute pyelonephritis. If approved, tebipenem HBr will be a novel oral formulation of tebipenem, a carbapenem-class antibiotic marketed in Japan since 2009 for specific pediatric infections.

It is currently in phase III stage of development is being developed by Spero Therapeutics.

Cell wall inhibitors: Therapeutic Assessment

This segment of the report provides insights about the different Cell wall inhibitors drugs segregated based on following parameters that define the scope of the report, such as:

Major Players working on Cell wall inhibitors

There are approx. 30+ key companies which are developing the Cell wall inhibitors. The companies which have their Cell wall inhibitors drug candidates in the most advanced stage, i.e. Preregistration include, Nabriva Therapeutics.

Phases

This report covers around 30+ products under different phases of clinical development like

• Late-stage products (Phase III)
• Mid-stage products (Phase II)
• Early-stage products (Phase I/II and Phase I) along with the details of
• Pre-clinical and Discovery stage candidates
• Discontinued & Inactive candidates

Route of Administration

Cell wall inhibitors pipeline report provides the therapeutic assessment of the pipeline drugs by the Route of Administration. Products have been categorized under various ROAs such as

• Infusion
• Intradermal
• Intramuscular
• Intranasal
• Intravaginal
• Oral
• Parenteral
• Subcutaneous
• Topical

Molecule Type

Products have been categorized under various Molecule types such as

• Vaccines
• Monoclonal Antibody
• Peptides
• Polymer
• Small molecule

Product Type

Drugs have been categorized under various product types like Mono, Combination and Mono/Combination.

Cell wall inhibitors: Pipeline Development Activities

The report provides insights into different therapeutic candidates in phase III, II, I, preclinical and discovery stage. It also analyses Cell wall inhibitors therapeutic drugs key players involved in developing key drugs.

Pipeline Development Activities

The report covers the detailed information of collaborations, acquisition and merger, licensing along with a thorough therapeutic assessment of emerging Cell wall inhibitors drugs.

Cell wall inhibitors Report Insights

• Cell wall inhibitors Pipeline Analysis
• Therapeutic Assessment
• Unmet Needs
• Impact of Drugs

Cell wall inhibitors Report Assessment

• Pipeline Product Profiles
• Therapeutic Assessment
• Pipeline Assessment
• Inactive drugs assessment
• Unmet Needs

Key Questions

Current Scenario and Emerging Therapies:

• How many companies are developing Cell wall inhibitors drugs?
• How many Cell wall inhibitors drugs are developed by each company?
• How many emerging drugs are in mid-stage, and late-stage of development for Cell wall inhibitors?
• What are the key collaborations (Industry-Industry, Industry-Academia), Mergers and acquisitions, licensing activities related to the Cell wall inhibitors therapeutics?
• What are the recent trends, drug types and novel technologies developed to overcome the limitation of existing therapies?
• What are the clinical studies going on for Cell wall inhibitors and their status?
• What are the key designations that have been granted to the emerging drugs?

Key Players

• Recce Pharmaceuticals
• Spero Therapeutics
• Nabriva Therapeutics
• Karveel Pharmaceuticals
• Seachaid Pharmaceuticals

Key Products

• RECCE-327
• RECCE-111
• Tebipenem pivoxil
• CONTEPO
• SNP021062
• SP1001
• SP-2078

This product will be delivered within 2 business days.